在NSCLC中NUP155和NDC1的相互作用:对于瘤进展来说是一个有希望的目标
Kai-Min Li1, Li-Fei Meng1, Zhi-Hao Yang1
1Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Frontiers in pharmacology
|December 25, 2024
概括
核孔复合蛋白NUP155和NDC1促进非小细胞肺癌 (NSCLC) 的进展. NUP155是NSCLC治疗的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 核孔综合体 (NPC) 蛋白质,包括NUP155,与各种癌症有关.
- 之前的研究将NUP155与侵袭性乳腺癌和肝细胞癌联系起来.
- 对于NUP155和NDC1在非小细胞肺癌 (NSCLC) 进展中的作用尚不清楚.
研究的目的:
- 调查NUP155和NDC1对非小细胞肺癌 (NSCLC) 进展的影响.
- 根据这些核孔复合蛋白的功能来确定NSCLC的潜在治疗点.
主要方法:
- 对NSCLC数据集的差异基因表达分析.
- 对已识别的基因进行功能丰富和卡普兰-梅尔生存分析.
- 实验验证使用西斑,殖民地形成,Transwell和CCK-8试验.
主要成果:
- 确定了6个差异表达的基因,包括NUP155和NDC1.
- 发现NUP155和NDC1与NUP53相互作用,这对核孔复合组合至关重要.
- 这些相互作用与促进NSCLC发展有关.
结论:
- NUP155和NDC1的相互作用促进了核毛孔复合体的组合,推动了NSCLC的进展.
- NUP155成为非小细胞肺癌治疗的有前途的治疗标.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
981
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Non-Canonical Wnt Signaling Pathways
7.2K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
134
